No matter how good something is, there can always come a point at which there is too much of it. One example of that can be found
in the rush to develop cancer therapeutics by so many companies, which may lead to diminishing returns for those companies as well as leave other therapeutic
areas to languish.
In December, DDNews columnist Peter Kissinger took some time to
celebrate instrumentation and all it has done to facilitate advances in the life sciences, and now he takes the time to shine a spotlight on the engineers
who make so much possible
As a patient-centric shift continues to sweep our healthcare system, pharmaceutical companies are
increasingly seeing the value of targeting treatments to specific patient populations, making the therapy more personal